Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2013, Article ID 946392, 4 pages
http://dx.doi.org/10.1155/2013/946392
Case Report

A Patient with HIV Treated with Ipilimumab and Stereotactic Radiosurgery for Melanoma Metastases to the Brain

1Departments of Neurosurgery, The Johns Hopkins University School of Medicine, Phipps 123 600 N. Wolfe Street, Baltimore, MD 21287, USA
2University of Maryland School of Medicine, Baltimore, MD 21210, USA
3Department of Radiation Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
4Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

Received 17 September 2013; Accepted 31 October 2013

Academic Editors: K. Jamil and P. F. Lenehan

Copyright © 2013 Jacob Ruzevick et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. J. Silverberg, C. Chao, W. A. Leyden et al., “HIV infection, immunodeficiency, viral replication, and the risk of cancer,” Cancer Epidemiology Biomarkers and Prevention, vol. 20, no. 12, pp. 2551–2559, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. L. K. Rodrigues, B. J. Klencke, K. Vin-Christian et al., “Altered clinical course of malignant melanoma in HIV-positive patients,” Archives of Dermatology, vol. 138, no. 6, pp. 765–770, 2002. View at Google Scholar · View at Scopus
  3. F. S. Hodi, S. J. O'Day, D. F. McDermott et al., “Improved survival with ipilimumab in patients with metastatic melanoma,” New England Journal of Medicine, vol. 363, no. 8, pp. 711–723, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Margolin, M. S. Ernstoff, O. Hamid et al., “Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial,” The Lancet Oncology, vol. 13, no. 5, pp. 459–465, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. J. S. Weber, A. Amin, D. Minor, J. Siegel, D. Berman, and S. J. O'Day, “Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial,” Melanoma Research, vol. 21, no. 6, pp. 530–534, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. Q. Leng, Z. Bentwich, E. Magen, A. Kalinkovich, and G. Borkow, “CTLA-4 upregulation during HIV infection: association with anergy and possible target for therapeutic intervention,” AIDS, vol. 16, no. 4, pp. 519–529, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. J. L. Riley, K. Schlienger, P. J. Blair et al., “Modulation of susceptibility to HIV-1 infection by the cytotoxic T lymphocyte antigen 4 costimulatory molecule,” Journal of Experimental Medicine, vol. 191, no. 11, pp. 1987–1997, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. J. P. Knisely, J. B. Yu, J. Flanigan, M. Sznol, H. M. Kluger, and V. L. Chiang, “Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival,” Journal of Neurosurgery, vol. 117, no. 2, pp. 227–233, 2012. View at Google Scholar
  9. J. L. Frazier, J. E. Han, M. Lim, and A. Olivi, “Immunotherapy combined with chemotherapy in the treatment of tumors,” Neurosurgery Clinics of North America, vol. 21, no. 1, pp. 187–194, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Robert, L. Thomas, I. Bondarenko et al., “Ipilimumab plus dacarbazine for previously untreated metastatic melanoma,” New England Journal of Medicine, vol. 364, no. 26, pp. 2517–2526, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Hoffmann, H. A. Horst, M. Weichenthal, and A. Hauschild, “Malignant melanoma and HIV infection—aggressive course despite immune reconstitution,” Onkologie, vol. 28, no. 1, pp. 35–37, 2005. View at Google Scholar · View at Scopus
  12. M. M. Burke, H. M. Kluger, M. Golden, K. N. Heller, A. Hoos, and M. Sznol, “Case report: response to ipilimumab in a patient with HIV with metastatic melanoma,” Journal of Clinical Oncology, vol. 29, no. 32, pp. e792–e794, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. V. Cecchinato, E. Tryniszewska, Z. M. Ma et al., “Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection,” Journal of Immunology, vol. 180, no. 8, pp. 5439–5447, 2008. View at Google Scholar · View at Scopus
  14. C. L. Day, D. E. Kaufmann, P. Kiepiela et al., “PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression,” Nature, vol. 443, no. 7109, pp. 350–354, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. A. A. Lugade, J. P. Moran, S. A. Gerber, R. C. Rose, J. G. Frelinger, and E. M. Lord, “Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor,” Journal of Immunology, vol. 174, no. 12, pp. 7516–7523, 2005. View at Google Scholar · View at Scopus
  16. E. F. Stamell, J. D. Wolchok, S. Gnjatic, N. Y. Lee, and I. Brownell, “The Abscopal effect associated with a systemic anti-melanoma immune response,” International Journal of Radiation Oncology, Biology, Physics, vol. 85, no. 2, pp. 293–295, 2013. View at Publisher · View at Google Scholar · View at Scopus